XT
CYTK icon

XTX Topco’s Cytokinetics CYTK Stock Holding History

XTX Topco’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.88M Buy
80,743
+56,890
+239% +$4.08M 0.09% 240
2026
Q1 		$1.57M Sell
23,853
-66,726
-74% -$4.24M 0.03% 1038
2025
Q4 		$5.76M Buy
90,579
+86,589
+2,170% +$5.39M 0.15% 97
2025
Q3 		$219K Buy
+3,990
New +$164K 0.01% 1773
2025
Q2 		– Sell
-7,357
Closed -$296K – 2513
2025
Q1 		$296K Sell
7,357
-2,293
-24% -$105K 0.02% 1416
2024
Q4 		$454K Sell
9,650
-221
-2% -$11.5K 0.04% 852
2024
Q3 		$521K Buy
+9,871
New +$550K 0.04% 788
2024
Q1 		– Sell
-4,178
Closed -$349K – 1928
2023
Q4 		$349K Sell
4,178
-14,418
-78% -$522K 0.08% 505
2023
Q3 		$548K Buy
+18,596
New +$619K 0.09% 341
2022
Q3 		– Sell
-16,811
Closed -$661K – 1150
2022
Q2 		$661K Buy
+16,811
New +$677K 0.27% 74

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

XTX Topco's CYTK Position: Q2 2026 in Review

XTX Topco increased its Cytokinetics (CYTK) stake by 239% in Q2 2026, buying an estimated $4.08M and bringing the position to 80,743 shares worth $6.88M. The position accounts for 0.09% of the portfolio, ranked #240.

XTX Topco first reported a position in CYTK in Q2 2022 and has held it in 10 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • XTX Topco held 80,743 shares of Cytokinetics worth $6.88M as of Q2 2026.
  • XTX Topco bought 56,890 Cytokinetics shares in Q2 2026, an estimated $4.08M.
  • Cytokinetics made up 0.09% of XTX Topco's portfolio in Q2 2026, its #240 holding.
  • XTX Topco first reported a position in Cytokinetics in Q2 2022 and has held it in 10 quarters since.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.